Innovation Pharmaceuticals Inc (IPIX)

[BooDog]

You and I seem to be on the exact same wavelength.

The Company is collaborating with a Regional Biocontainment Laboratory researcher investigating further research opportunities with Brilacidin as a treatment for the SARS-CoV-2 virus, other Human Coronaviruses (H-CoVs), and other types of viruses. Further, grant applications for federally-funded research are pending, and further grant applications are planned.


There is no set timeline. I call this a Trigger Event. A fully funded phase trial announced out of the blue based on what they're already working on. It would be a surprise for sure.

Brilacidin is very much the forefront of IPIX's future...

As a result of the advent of the COVID-19 pandemic, we were approached by several organizations, including two academic institutions having Biosafety Level 3 Laboratories (BSL-3), interested in evaluating Brilacidin as an experimental new drug for COVID-19 and its underlying coronavirus (SARS-CoV-2). Early research indicated that Brilacidin was a promising therapeutic candidate and subsequent extensive pre-clinical research in multiple human cell lines have lent further evidence and support for continued research into Brilacidin’s antiviral properties. Brilacidin has shown consistent in vitro inhibition in a cell-type independent manner in different strains of coronaviruses, alphaviruses and bunyaviruses. In light of the ongoing pandemic and drug development environment, we have prioritized development of Brilacidin for COVID-19, including the conduct of a Phase 2 randomized, blinded, placebo-controlled clinical trial of Brilacidin in patients hospitalized with moderate-to-severe COVID-19. The trial has fully enrolled, with the Company preparing for study unblinding, statistical analysis and reporting of data.



Brilacidin formulation development work is in progress: For treating ulcerative colitis, we are engaged in the development of an oral formulation (i.e. capsule or tablet). For treating oral mucositis we are engaged in optimizing an oral rinse formulation for the treatment of severe oral mucositis.

..."Someone's knocking on the door! Open the door, let 'em in!"

The possibilities in bio land are endless.

Message in reply to:

From Page 53 of 10K:

Liquidity and Capital Resources


Projected Future Working Capital Requirements - Next 12 Months

As of June 30, 2021, we had approximately $10.2 million in cash compared to $6.0 million of cash as of June 30, 2020, and as of the date of this filing, we have approximately $11.3 million in cash. We currently anticipate that future budget expenditures will be approximately $10.2 million for the next 12 months, including approximately $8.2 million for clinical activities, supportive research, and drug product. Alternatively, if we decide to pursue a more aggressive plan with our clinical trials, we will require additional sources of capital during the fiscal year 2022 to meet our working capital requirements for our planned clinical trials. Potential sources for capital include grant funding for COVID-19 research and equity financings (see below).